Видео ютуба по тегу Nct03734029

HER2-low expression in breast cancer
HER2-low expression in breast cancer
Detailed safety analysis from the DESTINY-Breast04 trial
Detailed safety analysis from the DESTINY-Breast04 trial
Patient-reported outcomes from DESTINY-Breast04
Patient-reported outcomes from DESTINY-Breast04
DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancer
DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancer
The exciting new field of HER2-low breast cancer
The exciting new field of HER2-low breast cancer
Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04
Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04
DESTINY-Breast04: T-DXd for patients with HER2-low mBC
DESTINY-Breast04: T-DXd for patients with HER2-low mBC
Advances in novel ADCs for HER2-expressing breast cancer
Advances in novel ADCs for HER2-expressing breast cancer
DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer
DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer
What to look forward to in breast cancer at ASCO 2022?
What to look forward to in breast cancer at ASCO 2022?
ASCO 2022: DESTINY-Breast04, PALOMA-2, rEECur
ASCO 2022: DESTINY-Breast04, PALOMA-2, rEECur
Breast cancer highlights at ASCO 2022
Breast cancer highlights at ASCO 2022
Novel treatment options for HER2-low breast cancer
Novel treatment options for HER2-low breast cancer
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
DESTINY-Breast04: practice-changing results for HER2-low breast cancer
DESTINY-Breast04: practice-changing results for HER2-low breast cancer
Pooled analysis of management of nausea and vomiting in patients treated with T-DXd
Pooled analysis of management of nausea and vomiting in patients treated with T-DXd
Key takeaways from ASCO 2022
Key takeaways from ASCO 2022
Where are we in sequencing ADCs in HR+ breast cancer?
Where are we in sequencing ADCs in HR+ breast cancer?
Dr Kalinsky on the Implications of DESTINY-Breast06 for T-DXd Use in HER2-Ultralow Breast Cancer
Dr Kalinsky on the Implications of DESTINY-Breast06 for T-DXd Use in HER2-Ultralow Breast Cancer